guest
Guest
- Messages
- 320
Could Imatinib help closing down the BBB a little bit?
http://www.sciencedaily.com/releases/2010/10/101014083341.htm
ScienceDaily (Oct. 15, 2010) While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.
"Our new results show that the blood-brain barrier is regulated by pericytes, and can be opened in a way that allows the passage of molecules of different sizes while keeping the brain's basic functions operating properly," says Christer Betsholtz, professor of vascular biology at the Department of Medical Biochemistry, who has led the study.
The blood-brain barrier is a term denoting the separation of blood from tissue by blood vessels that are extremely tight? Impermeable?. In other organs, the capillary walls let certain substances carried by the blood, such as the plasma proteins albumin and immunoglobulin, out into the surrounding tissue. In the brain, however, this pathway is closed off. This is essential for many reasons, one being that the plasma proteins are harmful to nerve cells.
In recent time, capillary permeability in the brain has been discussed as a factor of potential significance to neurodegenerative diseases, such as Alzheimer's, Parkinson's and ALS.
"Our new knowledge of how the BBB is regulated could be used in two ways," says Professor Betsholtz. "To protect the brain under conditions such as stroke and inflammation that lead to the opening of the BBB and the release of neurodamaging substances; and to open the barrier temporarily to allow the transport of drugs against neurodegenerative and other diseases of the brain."
In the study, which is now published in Nature, Professor Betsholtz and his research group show how this would be possible. The pericytes normally maintain the barrier function through an as-yet unknown molecular mechanism; in their absence, a special transport process called transcytosis opens a path through the capillary walls so that molecules of different sizes, including large plasma proteins, can pass from the blood into the brain. The pericytes also regulate another type of brain cell known as an astrocyte. Astrocytes contribute to the BBB through special extensions called end-feet which envelop the capillaries and regulate water and ion flows.
"Another interesting find is that the cancer drug Imatinib, which inhibits certain signal proteins for cell growth, has a similar effect in the presence of pericytes in that they also close the capillary wall transport paths," says Professor Christer Betsholtz.
Also involved in the study were researchers at the Sahlgrenska Academy in Gothenburg. The study was financed through grants from the Swedish Agency for Innovation Systems, the EU Sixth Framework Programme, the Swedish Cancer Society, the Knut and Alice Wallenberg Foundation, the Inga-Britt and Arne Lundberg Research Foundation and the Sderberg foundations.
http://www.sciencedaily.com/releases/2010/10/101014083341.htm
ScienceDaily (Oct. 15, 2010) While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.
"Our new results show that the blood-brain barrier is regulated by pericytes, and can be opened in a way that allows the passage of molecules of different sizes while keeping the brain's basic functions operating properly," says Christer Betsholtz, professor of vascular biology at the Department of Medical Biochemistry, who has led the study.
The blood-brain barrier is a term denoting the separation of blood from tissue by blood vessels that are extremely tight? Impermeable?. In other organs, the capillary walls let certain substances carried by the blood, such as the plasma proteins albumin and immunoglobulin, out into the surrounding tissue. In the brain, however, this pathway is closed off. This is essential for many reasons, one being that the plasma proteins are harmful to nerve cells.
In recent time, capillary permeability in the brain has been discussed as a factor of potential significance to neurodegenerative diseases, such as Alzheimer's, Parkinson's and ALS.
"Our new knowledge of how the BBB is regulated could be used in two ways," says Professor Betsholtz. "To protect the brain under conditions such as stroke and inflammation that lead to the opening of the BBB and the release of neurodamaging substances; and to open the barrier temporarily to allow the transport of drugs against neurodegenerative and other diseases of the brain."
In the study, which is now published in Nature, Professor Betsholtz and his research group show how this would be possible. The pericytes normally maintain the barrier function through an as-yet unknown molecular mechanism; in their absence, a special transport process called transcytosis opens a path through the capillary walls so that molecules of different sizes, including large plasma proteins, can pass from the blood into the brain. The pericytes also regulate another type of brain cell known as an astrocyte. Astrocytes contribute to the BBB through special extensions called end-feet which envelop the capillaries and regulate water and ion flows.
"Another interesting find is that the cancer drug Imatinib, which inhibits certain signal proteins for cell growth, has a similar effect in the presence of pericytes in that they also close the capillary wall transport paths," says Professor Christer Betsholtz.
Also involved in the study were researchers at the Sahlgrenska Academy in Gothenburg. The study was financed through grants from the Swedish Agency for Innovation Systems, the EU Sixth Framework Programme, the Swedish Cancer Society, the Knut and Alice Wallenberg Foundation, the Inga-Britt and Arne Lundberg Research Foundation and the Sderberg foundations.